SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $509,681,144 |
| Positions | 30 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| KINIKSA PHARMACEUTICALS INTL | KNSA | ORD SHS CL A | $58,710,577 | 918,070 |
| RELAY THERAPEUTICS INC | RLAY | COM | $55,832,979 | 2,984,125 |
| LB PHARMACEUTICALS INC | LBRX | COM SHS | $44,663,240 | 1,376,159 |
| RELMADA THERAPEUTICS INC | RLMD | COM | $44,227,990 | 6,391,328 |
| ALTO NEUROSCIENCE INC | ANRO | COM SHS | $35,706,910 | 1,353,047 |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $34,587,464 | 354,816 |
| ALKERMES PLC | ALKS | SHS | $28,496,383 | 543,876 |
| SAVARA INC | SVRA | COM | $21,267,868 | 3,452,576 |
| VAXCYTE INC | PCVX | COM | $17,790,512 | 306,047 |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $16,697,055 | 329,006 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.